CO5611148A2 - Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina - Google Patents

Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina

Info

Publication number
CO5611148A2
CO5611148A2 CO04086713A CO04086713A CO5611148A2 CO 5611148 A2 CO5611148 A2 CO 5611148A2 CO 04086713 A CO04086713 A CO 04086713A CO 04086713 A CO04086713 A CO 04086713A CO 5611148 A2 CO5611148 A2 CO 5611148A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
inhibitor
pharmaceutically acceptable
composition according
pde3
Prior art date
Application number
CO04086713A
Other languages
English (en)
Spanish (es)
Inventor
Rolf Beumne
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CO5611148A2 publication Critical patent/CO5611148A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CO04086713A 2002-03-06 2004-09-03 Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina CO5611148A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06

Publications (1)

Publication Number Publication Date
CO5611148A2 true CO5611148A2 (es) 2006-02-28

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04086713A CO5611148A2 (es) 2002-03-06 2004-09-03 Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2291618T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1849468E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1482938T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP2091538B1 (en) * 2006-12-20 2010-03-03 Glaxo Group Limited 4-benzyl-1(2h)-phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US20080254029A1 (en) * 2007-04-11 2008-10-16 Alcon Research, Ltd. Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
KR101852222B1 (ko) 2011-02-07 2018-04-25 에스씨아이팜 에스에이알엘 낭포성 섬유증의 치료를 위한 신규 조성물
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
JP2017525721A (ja) * 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
BR112017007194B1 (pt) 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd Compostos de hidroxil purina e uso dos mesmos
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
HU220041B (hu) * 1993-07-02 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
EP1244654A1 (en) * 1999-10-25 2002-10-02 ALTANA Pharma AG Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
TW200306855A (en) 2003-12-01
US20050112069A1 (en) 2005-05-26
ZA200407104B (en) 2006-12-27
CA2478612C (en) 2013-12-10
ES2400670T3 (es) 2013-04-11
SG160197A1 (en) 2010-04-29
TWI347845B (en) 2011-09-01
ATE369134T1 (de) 2007-08-15
KR20040095255A (ko) 2004-11-12
UA80117C2 (uk) 2007-08-27
NO335254B1 (no) 2014-10-27
CN101257904A (zh) 2008-09-03
AU2003212268A1 (en) 2003-09-16
PT1849468E (pt) 2013-02-27
IS7438A (is) 2004-09-03
ES2291618T3 (es) 2008-03-01
EP1849468B1 (en) 2012-12-05
EP1482938A1 (en) 2004-12-08
HRP20040909B1 (en) 2012-11-30
EP1849468A3 (en) 2007-11-07
DE60315426T2 (de) 2008-07-03
SI1482938T1 (sl) 2007-12-31
PT1482938E (pt) 2007-11-15
WO2003074055A1 (en) 2003-09-12
EA200401137A1 (ru) 2005-04-28
CY1113894T1 (el) 2016-07-27
IL163336A (en) 2009-02-11
EP1482938B1 (en) 2007-08-08
MXPA04008460A (es) 2004-12-06
NO20044230L (no) 2004-12-06
PL371056A1 (en) 2005-06-13
HK1071308A1 (en) 2005-07-15
SI1849468T1 (sl) 2013-03-29
JP5150034B2 (ja) 2013-02-20
DK1849468T3 (da) 2013-02-04
PL211574B1 (pl) 2012-05-31
AU2003212268B2 (en) 2008-09-11
BR0308220A (pt) 2005-01-04
IS8760A (is) 2008-09-04
DE60315426D1 (de) 2007-09-20
DK1482938T3 (da) 2007-12-03
AR038858A1 (es) 2005-01-26
CA2478612A1 (en) 2003-09-12
HRP20040909A2 (en) 2005-08-31
EA200601592A1 (ru) 2006-12-29
EA007903B1 (ru) 2007-02-27
CY1106927T1 (el) 2012-09-26
JP2005524666A (ja) 2005-08-18
EP1849468A2 (en) 2007-10-31
NZ535611A (en) 2006-03-31
RS51018B (sr) 2010-10-31
RS78004A (sr) 2006-12-15
IS2536B (is) 2009-08-15
EA010886B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
CO5611148A2 (es) Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina
MX377251B (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
MX2010003923A (es) Formulacion farmaceutica de valsartan.
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AU2003226765A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
CO5560584A2 (es) Nueva combinacion
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina

Legal Events

Date Code Title Description
FG Application granted